Announcement on Convening the 2025 Semi-annual Performance Briefing
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Convening the 2025 Semi-annual Performance Briefing
Filed with SSE · · 3 pages · Chinese
Release
Shanghai Xiao Fang Pharmaceutical Co., Ltd. on 6ix
Earlier from Shanghai Xiao Fang Pharmaceutical
- Announcement on Resolutions of the 5th Meeting of the 2nd Board of Directors
- Announcement on Listing and Circulation of Partial Restricted Shares from Initial Public Offering
- Announcement on Voluntary Disclosure of Cooperation with Shanghai Skin Disease Hospital to Develop Class 1.1 New Traditional Chinese Medicine Compound Platycladus Orientalis Tincture for the Treatment of Hair Loss
- Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
- Announcement on Completion of Industrial and Commercial Change Registration
Later from Shanghai Xiao Fang Pharmaceutical
- Announcement on Entrusting Bojimed to Develop the Traditional Chinese Medicine Class 1.1 New Drug "Compound Platycodon Tincture" (for Treating Hair Loss)
- Announcement on Redemption at Maturity of Idle Raised Funds Used for Cash Management
- Announcement on Using Some Temporarily Idle Raised Funds for Cash Management
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
- Announcement on Change of Sponsor Representative for Continuous Supervision
Follow Shanghai Xiao Fang Pharmaceutical into a list and get an email when it puts out news.
Follow Shanghai Xiao Fang Pharmaceutical